Dashenlin Pharm Grp Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.02%

Dashenlin Pharm Grp Co Ltd (603233) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dashenlin Pharm Grp Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥4.60 Million
≈ $673.59K USD Cash + Short-term Investments

Total Assets

CN¥26.08 Billion
≈ $3.82 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Dashenlin Pharm Grp Co Ltd's Asset Resilience Ratio has changed over time. See Dashenlin Pharm Grp Co Ltd (603233) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Dashenlin Pharm Grp Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dashenlin Pharm Grp Co Ltd (603233) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥4.60 Million 0.02%
Total Liquid Assets CN¥4.60 Million 0.02%

Asset Resilience Insights

  • Limited Liquidity: Dashenlin Pharm Grp Co Ltd maintains only 0.02% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Dashenlin Pharm Grp Co Ltd Industry Peers by Asset Resilience Ratio

Compare Dashenlin Pharm Grp Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 30.29%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Shanghai Junshi Biosciences Co Ltd
SHG:688180
Biotechnology 4.28%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 83.49%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 41.74%

Annual Asset Resilience Ratio for Dashenlin Pharm Grp Co Ltd (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Dashenlin Pharm Grp Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.06% CN¥15.51 Million
≈ $2.27 Million
CN¥26.44 Billion
≈ $3.87 Billion
-0.12pp
2023-12-31 0.17% CN¥41.99 Million
≈ $6.14 Million
CN¥24.12 Billion
≈ $3.53 Billion
-0.27pp
2022-12-31 0.44% CN¥91.99 Million
≈ $13.46 Million
CN¥20.84 Billion
≈ $3.05 Billion
-0.19pp
2021-12-31 0.63% CN¥109.37 Million
≈ $16.00 Million
CN¥17.34 Billion
≈ $2.54 Billion
-4.96pp
2020-12-31 5.60% CN¥689.98 Million
≈ $100.97 Million
CN¥12.33 Billion
≈ $1.80 Billion
-6.08pp
2017-12-31 11.68% CN¥680.00 Million
≈ $99.51 Million
CN¥5.82 Billion
≈ $852.05 Million
+9.41pp
2014-12-31 2.27% CN¥53.69 Million
≈ $7.86 Million
CN¥2.37 Billion
≈ $346.10 Million
-0.30pp
2013-12-31 2.57% CN¥43.20 Million
≈ $6.32 Million
CN¥1.68 Billion
≈ $245.96 Million
-1.24pp
2012-12-31 3.81% CN¥37.97 Million
≈ $5.56 Million
CN¥996.51 Million
≈ $145.82 Million
--
pp = percentage points

About Dashenlin Pharm Grp Co Ltd

SHG:603233 China Biotechnology
Market Cap
$3.11 Billion
CN¥21.26 Billion CNY
Market Cap Rank
#4859 Global
#922 in China
Share Price
CN¥18.67
Change (1 day)
-0.27%
52-Week Range
CN¥15.58 - CN¥21.27
All Time High
CN¥57.53
About

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.